Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sun Communities names Ileana McAlary as general counsel and EVP
• AXT appoints Tracy Liu to its board of directors